

## **APPENDIX A**

# CURRICULUM VITAE

**Name:** Ian Hector FRAZER  
**Date of Birth:** 6th January 1953  
**Place of Birth:** Glasgow, Scotland  
**Nationality:** Australian Citizen

**Degrees:** BSc (Hons) Pathology (Edinburgh) 1974  
MB ChB (Edinburgh) 1977  
MD (Melbourne) 1988 "Humoral Immunity to Liver Antigens in Autoimmune liver disease"

**Awards:** BHERT award for Collaborative Research 1999  
Australian Biotechnology Award 1999  
Centenary Medal 2003, for services to cancer research  
John Curtin Medal 2005  
CSIRO Eureka Award for Leadership in Science 2005  
"The Australian" Australian of the Year 2006  
Australian of the Year 2006  
Suncorp Queenslander of the Year 2006  
Queensland Great Award 2006  
Distinguished Fellowship Award, Royal College of Pathologists 2006  
William Coley Medal, Cancer Research Institute New York 2006  
International Life Award (Sezione Ricerca Scientifica), Rome – January 2007  
Florey Medal, Sydney – March 2007  
Clunies Ross Award – Melbourne – April 2007  
International Achievement Summit Golden Plate award – New York - June 2007  
2007 Novartis Prize for Clinical Immunology – August 2007 – Rio de Janeiro  
Honorary Professor, Shihezi University  
Honorary Professor, Chengdu University

**Fellowships:** Royal College of Physicians of Edinburgh 1988  
Royal College of Pathologists of Australia 1989  
Australian Institute of Company Directors 2002  
Australian Academy of Science Technology and Engineering 2003  
Australian Academy of Science 2004  
Royal Australian College of General Practitioners 2007

**Travelling fellowships:** Eleanor Roosevelt Cancer Research Fellow (UICC) 1989  
Australian Academy of Sciences Travelling Fellowship 1992  
William Rudder Travelling Fellowship (QCF) 1993  
Christ's College Cambridge visiting Fellowship 2004

**Directorships:** For Profit organisations  
Coridon Pty Ltd 2002- date  
Implicit Biosciences Pty Ltd 2005- date  
Biopharmaceuticals Australia Development Pty Ltd 2007  
Not for Profit organisation  
Diabetes Vaccine Development Centre 2003 – date

Cancer Council Australia 2002 – date (currently President)  
JDRF Pancreatic Islet Transplant Program 2005 – date

**Employment History:**

1977	House Officer, Roodlands Hospital, Haddington
1977	House Officer, Eastern General Hospital, Edinburgh
1978	Senior House Officer, Medical Renal Unit, Royal Infirmary, Edinburgh
1979	Senior House Officer, Department of Medicine, Eastern General Hospital, Edinburgh
1980	Registrar, Medical Renal Unit, Royal Infirmary, Edinburgh
1981/85	Senior Research Officer, Walter & Eliza Hall Institute, Melbourne
	Assistant, Department of Medicine, University of Melbourne
	Assistant Physician, Clinical Research Unit, Walter & Eliza Hall Institute
1985/88	Senior Lecturer, Department of Medicine, University of Queensland
1985/99	Director, Division of Clinical Immunology, Princess Alexandra Hospital, Queensland
1989/93	Associate Professor, Department of Medicine, University of Queensland
1994-	Professor, Department of Medicine, University of Queensland
1991-	Director, Centre for Immunology and Cancer Research, University of Queensland

### Significant invited lectures:

Date	Location	Organisation	Lecture
October 2007	Brisbane	Prince Charles Hospital Foundation	Woolcock Oration
October 2007	Gold Coast	RANZCOG	Arthur Wilson Memorial Oration
September 2007	Sydney	APEC Business Summit 2007	Panellist in session “Educating our people for the future: population, skills and innovation”
July 07	Perth	University of Western Australia	The Sir Wallace Kyle Oration
July 07	Melbourne	Sir Edward Dunlop Medical Research Foundation	“Recent developments and medical advances in medical research”
April 07	Perth	Raine Medical Research Foundation	Raine Oration
April 07	Melbourne	Clunies Ross Dinner	Keynote Address
March 07	Bangkok	Australian Embassy	Keynote Speaker
March 07	Sydney	Pathology Update 2007	Keynote Speaker – Eva Raik Lecture “Cancer Control in the 21 <sup>st</sup> Century”
November 2006	Brisbane	Australian Healthcare Association Congress	Ron Tindle Oration
October 2006	Brisbane	RACP 49 <sup>th</sup> Annual Scientific Conference	Dr William Arnold Connolly Oration
July 2006	Sydney	Biotech Summit	Key opening address “Leading the charge on Vaccine R&D”
July 2006	Brisbane	Earth Dialogues Conference	“How can we shift away from the short term, insular management to honour our long term responsibilities”
July 2006	Perth	HERDSA Conference	Keynote “How can a Scientist survive in academia in the current economic climate”
June 2006	New York	CRI New York Awards Ceremony	Keynote Talk

Date	Location	Organisation	Lecture
June 2006	Portugal	MSD/SPMSD Symposium at the International Congress on Infectious Diseases	“Immune response and long term protection with quadrivalent HPV vaccine: what we know now and what we will know later”
May 2006	Brisbane	Future Summit 2006	Keynote Address “Australia as a knowledge based economy: earning social credit and a positive balance of trade in the 21 <sup>st</sup> Century Global Village”
2005 December	Washington	ICAAC	Invited speaker
2005 March	Geneva	WHO meeting on HPV Vaccines	Speaker/rapporteur
2004 September	Paris	EUROCONFERENCE Vaccines 3: Frontiers in Vaccine Development	Plenary Speaker
2004 February	Bangalore	Australia- India Biotechnology conference	Keynote lecture
2003 September	Auckland	Australasian Society of Microbiology	Bazeley Oration
2003 April	Los Angeles	Development of Therapeutic Cancer Vaccines	Plenary speaker
2002 November	Washington	Pan American Health Organisation 100 <sup>th</sup> Anniversary meeting	Plenary Speaker
2002 July	Washington	NIH Summit on Papillomavirus Vaccines	Plenary Speaker
2001 December	Canberra	Australasian Society for Immunology	Gordon Ada lecture
2000 October	New York	Cancer Research Institute	Plenary Speaker
1999 November	Buenos Aires	World Colposcopy Conference	Keynote Speaker

In 2006 as Australian of the Year I gave over 50 lectures and addresses within Australia

### Life Synopsis:

Ian Frazer is director of the Diamantina Institute of Cancer, Immunology and Metabolic Medicine, a research institute of the University of Queensland at the Princess Alexandra Hospital in Brisbane. He was trained as a renal physician and clinical immunologist in Edinburgh, Scotland before emigrating in 1981 to Melbourne, Australia to continue his clinical training and to pursue studies in viral immunology and autoimmunity at the Walter and Eliza Hall institute of Medical Research with Prof Ian Mackay. In 1985 he moved to Brisbane to take up a teaching post with the University of Queensland, and he now holds a personal chair as head of the Diamantina Institute. This centre which Dr Frazer founded in 1991 as the Centre for Immunology and Cancer Research now employs over 80 researchers and trains about 50 postgraduate students. He is currently president of the Cancer Council Australia. Dr Frazer teaches immunology to undergraduate and graduate students of the University.

Dr Frazer's current laboratory research is focussed on development of immunotherapeutic vaccines for papillomavirus associated cancers, for which he holds research funding from several Australian and US funding bodies, and on understanding the local regulation of vaccine developed immune effector responses

in skin. He is pursuing field trials of delivery of HPV vaccines and other methods of cervical cancer control with colleagues in Nepal and Vanuatu, with assistance from Ausaid and the Australian Cervical Cancer Foundation, and advises the WHO on papillomavirus vaccine deployment.

#### **Commercialisation:**

Dr Frazer consults for CSL Ltd, Uniquist and Merck in the field of prophylactic and therapeutic papillomavirus vaccines. He is a member of the Merck global advisory board for HPV vaccines and the Science Alliance Advisory Board of Schering Plough Pty Ltd. He consults on an intermittent basis for several biotechnology companies in Australia and the USA. He is a named inventor on patents relating to HPV prophylactic and therapeutic vaccines licenced to CSL, Merck and GSK, on patents on DNA vaccines and on optimising therapeutic protein expression licenced to Coridon Pty Ltd, and on patents relating to optimising immunotherapy.

#### **Research Funding:**

Dr Frazer is the inaugural holder of the Queensland government Smart State premier's fellowship, worth \$2.5m over 5 years. Dr Frazer has held continuous research funding from the NHMRC since 1985, mostly relating to papillomaviruses or to tumour immunology. He is currently a joint CI on an NHMRC program grant and a NHMRC/Wellcome program grant, together worth >\$2m/year. He also holds competitive project grants from NHMRC, the Queensland Cancer Fund, and the Cancer Research Institute of New York.

#### **Significant contributions to Biomedical Research**

Since 1983, Dr Frazer has pursued an interest in development of vaccines to prevent human papillomavirus(HPV) infection and the ~0.5m annual deaths from papillomavirus related human cancers in the cervix and elsewhere. In 1985, with colleagues in Melbourne, he demonstrated, at a time when the association of papillomavirus infection with cervical cancer was still contentious, that papillomavirus infection also contributed to anal precancer, particularly in men with immunosuppression as a result of HIV/AIDS, probably the first confirmed example of the relevance of immune surveillance to control of a virus associated cancer in humans. In 1990, he and his then postdoctoral scientist, Dr Jian Zhou, developed the technology for producing human papillomavirus virus like particles. This technology, licenced through the University of Queensland, is now the basis of vaccines recently brought to market by GSK (Cervarix) and Merck (Gardasil) to prevent cervical cancer. The HPV vaccine is only the second vaccine to be produced using recombinant DNA technology, which was necessary because papillomaviruses could not be grown in cell culture. The development of HPV virus like particles was an early product of the application of comparative genomics, as sequence alignment for the genes for the major capsid proteins of a range of papillomaviruses showed that expression of the major capsid protein of the HPV16 virus from the second initiation codon in eukaryotic cells was likely to induce particle formation where conventional expression strategies had failed. Dr Frazer has also developed therapeutic vaccines for chronic HPV infection, one of which is in Phase 2b clinical trials in China and Brisbane with funding from the Cancer Research Institute of New York and The Wellcome Foundation. Dr Frazer has also developed a technology for improving the immune response to polynucleotide vaccines based on differential preferences for codon usage between cells of different lineages, which has been licenced to Coridon Pty Ltd and is currently being used to develop polynucleotide vaccines for Herpesviruses.

Peer reviewed original articles

- (1) Frazer IH, Eke N, Laing MS. Is infusion phlebitis preventable? *Br Med J* 1977;2(6081):232.
- (2) Prescott LF, Illingworth RN, Critchley JA, Frazer IH, Stirling ML. Acute haemolysis and renal failure after nomifensine overdosage. *Br Med J* 1980;281(6252):1392-3.
- (3) Burns GF, Librach CL, Frazer IH, Kronborg IJ, Mackay IR. Spontaneous reverse hemolytic plaque formation. III. Monocyte-mediated suppression of elevated plaque formation in autoimmune disease. *Clin Immunol Immunopathol* 1982;24(3):386-95.
- (4) Frazer IH, Mackay IR. T lymphocyte subpopulations defined by two sets of monoclonal antibodies in chronic active hepatitis and systemic lupus erythematosus. *Clin Exp Immunol* 1982;50(1):107-14.
- (5) Kronborg IJ, Frazer IH, Mackay IR. Autoantibodies to liver antigens in chronic liver disease. I. A radioimmunoassay for antibody to liver membrane antigens. *J Clin Lab Immunol* 1982;9(3):207-11.
- (6) Douglas JG, Gough J, Preston PG, Frazer IH, Haslett C, Chalmers S, et al. Long-term efficacy of fenfluramine in treatment of obesity. *Lancet* 1983;1(8321):384-6.
- (7) Frazer IH, Mackay IR. A rapid micromethod for evaluating T cell subsets in blood using monoclonal antisera. *J Immunol Methods* 1983;57(1-3):137-44.
- (8) Frazer IH, Kronborg IJ, Mackay IR. Antibodies to liver membrane antigens in chronic active hepatitis (CAH). II. Specificity for autoimmune CAH. *Clin Exp Immunol* 1983;54(1):213-8.
- (9) Frazer IH, Sarngadharan MG, Mackay IR, Gallo RC. Antibody to human T cell leukaemia virus type III in Australian homosexual men with lymphadenopathy. *Med J Aust* 1984;141(5):274-6.
- (10) Frazer IH, Mackay IR. Antibodies to liver cell membrane antigens in chronic active hepatitis (CAH). III. Partial characterization of the liver cell membrane antigens and comparison of reactivities in sera from patients with various liver diseases. *Clin Exp Immunol* 1984;57(2):429-37.
- (11) Macgeorge J, Frazer IH, Cunningham A. Autoantibodies, sheep cell agglutinins and anti-albumin antibodies in alcoholic liver disease. *J Clin Lab Immunol* 1984;13(1):21-4.
- (12) Cunningham AL, Mackay IR, Frazer IH, Brown C, Pedersen JS, Toh B, et al. Antibody to G-actin in different categories of alcoholic liver disease: quantification by an ELISA and significance for alcoholic cirrhosis. *Clin Immunol Immunopathol* 1985;34(2):158-64.
- (13) Frazer IH, Mackay IR, Jordan TW, Whittingham S, Marzuki S. Reactivity of anti-mitochondrial autoantibodies in primary biliary cirrhosis: definition of two novel mitochondrial polypeptide autoantigens. *J Immunol* 1985;135(3):1739-45.
- (14) Frazer IH, Mackay IR. A graphical presentation of counts of T lymphocyte subpopulations and Th-Ts ratios. *Pathology* 1985;17(1):62-3.
- (15) Frazer IH, Collins EJ, Fox JS, Jones B, Oliphant RC, Mackay IR. Assessment of delayed-type hypersensitivity in man: a comparison of the "Multitest" and conventional intradermal injection of six antigens. *Clin Immunol Immunopathol* 1985;35(2):182-90.
- (16) Frazer IH, Mackay IR, Bell J, Becker G. The cellular infiltrate in the liver in auto-immune chronic active hepatitis: analysis with monoclonal antibodies. *Liver* 1985;5(3):162-72.

- (17) Mackay IR, Frazer IH, Toh BH, Pedersen JS, Alter HJ. Absence of autoimmune serological reactions in chronic non A, non B viral hepatitis. *Clin Exp Immunol* 1985;61(1):39-43.
- (18) De Moerloose PA, Frazer IH, Sewell WA, Collins EJ, Mackay IR. Cell-mediated immunity to hepatitis B virus antigens in mice: correlation of in vivo and in vitro assays. *Clin Exp Immunol* 1986;64(2):285-94.
- (19) Frazer IH, Mackay IR, Crapper RM, Jones B, Gust ID, Sarngadharan M, et al. Immunological abnormalities in asymptomatic homosexual men: correlation with antibody to HTLV-III and sequential changes over two years. *Q J Med* 1986;61(234):921-33.
- (20) Frazer IH, Medley G, Crapper RM, Brown TC, Mackay IR. Association between anorectal dysplasia, human papillomavirus, and human immunodeficiency virus infection in homosexual men. *Lancet* 1986;2(8508):657-60.
- (21) Frazer IH, Mackay IR, Battye F. A rapid micromethod for the enumeration of T cell subsets in blood by epifluorescence microscopy. *Methods Enzymol* 1986;121:748-58.
- (22) Crapper RM, Frazer IH, Mackay IR, Iscaro A, Bradford DL. Immunoregulatory defects associated with infection with the AIDS virus, HTLV-III. *Concepts Immunopathol* 1987;4:243-60.
- (23) Frazer IH, Jordan TW, Collins EC, Andrews P, Mackay IR. Antibody to liver membrane antigens in chronic active hepatitis. IV. Exclusion of specific reactivity to polypeptides and glycolipids by immunoblotting. *Hepatology* 1987;7(1):4-10.
- (24) Frazer IH, Jones B, Dimitrakakis M, Mackay IR. Intramuscular versus low-dose intradermal hepatitis B vaccine. Assessment by humoral and cellular immune response to hepatitis B surface antigen. *Med J Aust* 1987;146(5):242-5.
- (25) Emmerson BT, Hazelton RA, Frazer IH. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. *Arthritis Rheum* 1988;31(3):436-40.
- (26) Frazer IH, McCamish M, Hay I, North P. Influence of human immunodeficiency virus antibody testing on sexual behaviour in a "high-risk" population from a "low-risk" city. *Med J Aust* 1988;149(7):365-8.
- (27) Kennedy L, Buntine DW, O'Connor D, Frazer IH. Human papillomavirus--a study of male sexual partners. *Med J Aust* 1988;149(6):309-11.
- (28) Zachar V, Mikulecky M, Mayer V, Mackay I, Frazer IH. A biometrical view on normal values of CD4 and CD8 lymphocyte counts in peripheral blood. *Pathology* 1988;20(4):358-60.
- (29) Field M, Tate J, Kunze H, Frazer IH. Cerebral dysfunction with evidence of cerebral HIV infection amongst asymptomatic HIV seropositive subjects. *Aust N Z J Med* 1989;19(6):694-9.
- (30) Renouf JA, Wood A, Frazer IH, Thong YH, Chalmers AH. Depressed activities of purine enzymes in lymphocytes of patients infected with human immunodeficiency virus. *Clin Chem* 1989;35(7):1478-81.
- (31) Selvey L, Buntine DW, Kennedy L, Frazer IH. Male partners of women with genital human papillomavirus infection. An assessment of colposcopic abnormalities by histological examination and human papillomavirus hybridization. *Med J Aust* 1989;150(9):479-80,482.
- (32) Chalmers AH, Hare C, Woolley G, Frazer IH. Lymphocyte ectoenzyme activity compared in healthy persons and patients seropositive to or at high risk of HIV infection. *Immunol Cell Biol* 1990;68(Pt 2):81-5.



- (33) Mundlos S, Mackay IR, Frazer IH, Rowley M. A neonatally tolerant mouse model to assess pathogenicity of human autoantibodies. *J Immunol Methods* 1990;127(2):279-84.
- (34) Selvey LA, Tindle RW, Geysen HM, Haller CJ, Smith JA, Frazer IH. Identification of B-epitopes in the human papillomavirus 18 E7 open reading frame protein. *J Immunol* 1990;145(9):3105-10.
- (35) Smillie AE, Tindle RW, O'Connor DT, Kennedy L, Frazer IH. Humoral response to Human Papillomavirus Type 16 and 18 open reading frame antigens in subjects with anogenital papillomavirus infections and controls. *Immunol Inf Dis* 1990;1:13-7.
- (36) Tindle RW, Smith JA, Geysen HM, Selvey LA, Frazer IH. Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein. *J Gen Virol* 1990;71(Pt 6):1347-54.
- (37) Tindle RW, Zhou WD, Saul A, Frazer IH. The molecular specificity of linear B-epitopes in the E7 open reading frame protein of human papillomavirus 16 defined by monoclonal antibodies. *Pept Res* 1990;3(4):162-6.
- (38) Zevering Y, Houghten RA, Frazer IH, Good MF. Major population differences in T cell response to a malaria sporozoite vaccine candidate. *Int Immunol* 1990;2(10):945-55.
- (39) Hogan PG, Frazer IH, International study group. A randomised placebo controlled study of Interferon alpha2a as treatment for recurrent genital warts. *JAMA* 1991;265:2684-7.
- (40) Terry SJ, Ford MJ, Sircus W, Suttle NF, Frazer IH, Munro JF. Zinc deficiency and the short bowel syndrome. *J Trace Elements Exp Med* 1991;4:85-8.
- (41) Tindle RW, Fernando GJ, Sterling JC, Frazer IH. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B- cell epitopes from cervical cancer-associated human papillomavirus genotypes. *Proc Natl Acad Sci USA* 1991;88(13):5887-91.
- (42) Zhou J, Doorbar J, Sun XY, Crawford LV, McLean CS, Frazer IH. Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein. *Virology* 1991;185(2):625-32.
- (43) Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. *Virology* 1991;185(1):251-7.
- (44) Zhou J, Crawford L, Sun XY, Frazer IH. The hygromycin-resistance-encoding gene as a selection marker for vaccinia virus recombinants. *Gene* 1991;107(2):307-12.
- (45) Lawton G, Thomas S, Schonrock J, Monsour F, Frazer IH. Human papillomaviruses in normal oral mucosa: a comparison of methods for sample collection. *J Oral Pathol Med* 1992;21(6):265-9.
- (46) Selvey LA, Dunn LA, Murray B, Tindle RW, Frazer IH. An ELISA capture assay for the E7 transforming proteins of HPV16 and HPV18. *J Virol Methods* 1992;37(2):119-27.
- (47) Tindle RW, Murray B, Herd K, O'Connor DT, Kennedy L, Frazer IH. Humoral immune responses to the E7 open reading frame of HPV16 in subjects with anogenital papillomavirus infection and controls. *Immunol Inf Dis* 1992;2:223-8.
- (48) Zhou J, Sun XY, Fernando GJ, Frazer IH. The vaccinia virus K2L gene encodes a serine protease inhibitor which inhibits cell-cell fusion. *Virology* 1992;189(2):678-86.
- (49) Zhou J, Sun XY, Davies H, Crawford L, Park D, Frazer IH. Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. *Virology* 1992;189(2):592-9.

- (50) Frazer IH, Leonard JH, Schonrock J, Wright RG, Kearsley JH. HPV DNA in oropharyngeal squamous cell cancers: comparison of results from four DNA detection methods. *Pathology* 1993;25(2):138-43.
- (51) Fredericks BD, Balkin A, Daniel HW, Schonrock J, Ward B, Frazer IH. Transmission of human papillomaviruses from mother to child [see comments]. *Aust NZ J Obstet Gynaecol* 1993;33(1):30-2.
- (52) International study group, Frazer IH. Randomised placebo controlled double blind combined therapy with laser surgery and systemic interferon alfa-2a in the treatment of ano-genital condylomata acuminatum. *J Infect Dis* 1993;167:824-9.
- (53) Park DS, Selvey LA, Kelsall SR, Frazer IH. Human papillomavirus type 16 E6, E7 and L1 and type 18 E7 proteins produced by recombinant baculoviruses. *J Virol Methods* 1993;45(3):303-18.
- (54) Zhou J, Sun XY, Frazer IH. Glycosylation of human papillomavirus type 16 L1 protein. *Virology* 1993;194(1):210-8.
- (55) Zhou J, Stenzel DJ, Sun XY, Frazer IH. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. *J Gen Virol* 1993;74(Pt 4):763-8.
- (56) Selvey LA, Dunn LA, Tindle RW, Park DS, Frazer IH. Human papillomavirus (HPV) type 18 E7 protein is a short-lived steroid-inducible phosphoprotein in HPV-transformed cell lines. *J Gen Virol* 1994;75(Pt 7):1647-53.
- (57) Thomas S, Brennan J, Martel G, Frazer IH, Montesano R, Sidransky D, et al. Mutations in the conserved regions of p53 are infrequent in betel-associated oral cancers from Papua New Guinea. *Cancer Res* 1994;54(13):3588-93.
- (58) Zhao XM, Green M, Frazer IH, Hogan P, O'Brien MF. Donor-specific immune response after aortic valve allografting in the rat. *Ann Thorac Surg* 1994;57(5):1158-63.
- (59) Zhou J, Sun XY, Louis K, Frazer IH. Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence. *J Virol* 1994;68(2):619-25.
- (60) Fernando GJ, Tindle RW, Frazer IH. T-helper epitopes of the E7 transforming protein of cervical cancer associated human papillomavirus type 18 (HPV18). *Virus Res* 1995;36(1):1-13.
- (61) Fernando GJ, Stenzel DJ, Tindle RW, Merza MS, Morein B, Frazer IH. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. *Vaccine* 1995;13(15):1460-7.
- (62) Frazer IH, Leippe DM, Dunn LA, Liem A, Tindle RW, Fernando GJ, et al. Immunological responses in human papillomavirus 16 E6/E7- transgenic mice to E7 protein correlate with the presence of skin disease. *Cancer Res* 1995;55(12):2635-9.
- (63) Muller M, Gissmann L, Cristiano RJ, Sun XY, Frazer IH, Jenson AB, et al. Papillomavirus capsid binding and uptake by cells from different tissues and species. *J Virol* 1995;69(2):948-54.
- (64) Sun XY, Frazer IH, Muller M, Gissmann L, Zhou J. Sequences required for the nuclear targeting and accumulation of human papillomavirus type 6B L2 protein. *Virology* 1995;213(2):321-7.
- (65) Armstrong DK, Maw RD, Dinsmore WW, Blaakaer J, Correa MA, Falk L, et al. Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts. *Genitourin Med* 1996;72(2):103-7.

- (66) Hogan P, Duplock L, Green M, Smith S, Gall KL, Frazer IH, et al. Human aortic valve allografts elicit a donor-specific immune response. *J Thorac Cardiovasc Surg* 1996;112(5):1260-6.
- (67) Londono LP, Chatfield S, Tindle RW, Herd K, Gao XM, Frazer IH, et al. Immunisation of mice using *Salmonella typhimurium* expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. *Vaccine* 1996;14(6):545-52.
- (68) Qi YM, Peng SW, Hengst K, Evander M, Park DS, Zhou J, et al. Epithelial cells display separate receptors for papillomavirus VLPs and for soluble L1 capsid protein. *Virology* 1996;216(1):35-45.
- (69) Dunn LA, Evander M, Tindle RW, Bulloch AL, De Kluyver RL, Fernando GJ, et al. Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. *Virology* 1997 Aug 18;235(1):94-103.
- (70) Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. *J Virol* 1997;71(3):2449-56.
- (71) Herd K, Fernando GJP, Dunn LA, Frazer IH, Lambert P, Tindle RW. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein. *Virology* 1997;231(1):155-65.
- (72) Fernando GJP, Stewart TJ, Tindle RW, Frazer IH. Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term. *Scand J Immunol* 1998 May;47(5):459-65.
- (73) Fernando GJP, Stewart TJ, Tindle RW, Frazer IH. Th2-type CD4<sup>+</sup> cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. *J Immunol* 1998 Sep 1;161(5):2421-7.
- (74) Frazer IH, Fernando GJP, Fowler N, Leggatt GR, Lambert PF, Liem A, et al. Split tolerance to a viral antigen expressed in thymic epithelium and keratinocytes. *Eur J Immunol* 1998 Sep;28(9):2791-800.
- (75) Green MK, Walsh MD, Dare A, Hogan PG, Zhao XM, Frazer IH, et al. Histologic and immunohistochemical responses after aortic valve allografts in the rat. *Ann Thorac Surg* 1998 Dec;66(6):S216-S220.
- (76) Kulski JK, Sadleir JW, Kelsall SR, Cicchini MS, Shellam G, Peng SW, et al. Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies. *Virology* 1998 Apr 10;243(2):275-82.
- (77) Liu XS, Abdul-Jabbar I, Qi YM, Frazer IH, Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. *Virology* 1998 Dec 5;252(1):39-45.
- (78) Peng SW, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. *Virology* 1998 Jan 5;240(1):147-57.
- (79) Zhao KN, Sun XY, Frazer IH, Zhou J. DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. *Virology* 1998 Apr 10;243(2):482-91.
- (80) Azoury-Ziadeh R, Herd K, Fernando GJ, Frazer IH, Tindle RW. T helper epitopes identified within the E6 transforming protein of cervical cancer associated human papillomavirus type 16. *Viral Immunol* 1999 Jan 1;12(4):297-312.
- (81) Evans DM, Frazer IH, Martin NG. Genetic and environmental causes of variation in basal levels of blood cells. *Twins Research* 1999;2(2):250-7.

- (82) Fang NX, Frazer IH, Zhou J, Fernando GJP. Post translational modifications of recombinant human Papillomavirus type 6b major capsid protein. *Virus Res* 1999 Apr;60(2):113-21.
- (83) Fernando GJP, Murray B, Zhou J, Frazer IH. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. *Clin Exp Immunol* 1999 Mar;115(3):397-403.
- (84) Frazer IH, Thomas R, Zhou J, Leggatt GR, Dunn LA, McMillan NA, et al. Potential strategies utilised by papillomavirus to evade host immunity. *Immunol Rev* 1999;168(2):131-42.
- (85) Frazer IH, Tindle RW, Fernando GJ, Malcolm K, Herd K, McFadyyn S, et al. Safety and immunogenicity of HPV16 E7/Algamulin immunotherapy for Cervical Cancer. In: Tindle RW, editor. *Vaccines for Human Papillomavirus Infection and Anogenital Disease*. Austin, Texas: Landes Bioscience; 1999. p. 91-104.
- (86) Hilditch-Maguire PA, Lieppe DM, West D, Lambert PF, Frazer IH. T cell-mediated and non-specific inflammatory mechanisms contribute to the skin pathology of HPV 16 E6E7 transgenic mice. *Intervirology* 1999 Jan;42(1):43-50.
- (87) McMillan NAJ, Payne E, Frazer IH, Evander M. Expression of the  $\alpha 6$  integrin confers papillomavirus binding upon receptor-negative B-cells. *Virology* 1999 Sep 1;261(2):271-9.
- (88) Peng SW, Qi YM, Hengst K, Christensen N, Kennedy L, Frazer IH, et al. Capture ELISA and in vitro cell binding assay for the detection of antibodies to human papillomavirus type 6b virus-like particles in anogenital warts patients. *Pathology* 1999;31:418-22.
- (89) Zhao KN, Frazer IH, Liu W, Williams M, Zhou J. Nucleotides 1506-1625 of Bovine Papillomavirus type 1 Genome Can Enhance DNA Packaging by L1/L2 Capsids. *Virology* 1999;259:211-8.
- (90) Zhou J, Liu WJ, Peng SW, Sun XY, Frazer IH. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. *J Virol* 1999 Jun;73(6):4972-82.
- (91) Dicker AJ, Popa C, Dahler AL, Serewko MM, Hilditch-Maguire PA, Frazer IH, et al. E2F-1 induces proliferation-specific genes and suppresses squamous differentiation-specific genes in human epidermal keratinocytes. *Oncogene* 2000 Jun 8;19(25):2887-94.
- (92) Fang NX, Frazer IH, Fernando GJ. Differences in the post-translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system compared with a vaccinia virus system. *Biotechnol Appl Biochem* 2000;32:27-33.
- (93) Frazer IH, Howard J, Cox C, McFadyyn S. Predictors of genital warts amongst attendees at two family planning clinics. *Venereology* 2000;13(4):157-65.
- (94) Jabbar IA, Fernando GJ, Saunders NA, Aldovini A, Young RA, Malcolm K, et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 Proteins. *Vaccine* 2000;18(22):2444-53.
- (95) Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. *Virology* 2000 Aug 1;273(2):374-82.
- (96) Malcolm K, Meschede W, Pawlita M, Koutsky LA, Frazer IH. Multiple conformational epitopes are recognized by natural and induced immunity to the E7 protein of human papilloma virus type 16 in man. *Intervirology* 2000 May;43(3):165-73.
- (97) Zhang LF, Zhou J, Chen S, Cai LL, Bao QY, Zheng FY, et al. HPV6b virus like particles are potent immunogens without adjuvant in man. *Vaccine* 2000 Jan 6;18(11-12):1051-8.

- (98) Zhao KN, Hengst K, Liu WJ, Liu YH, Liu XS, McMillan NAJ, et al. BPV1 E2 protein enhances packaging of full-length plasmid DNA in BPV1 pseudovirions. *Virology* 2000 Jul 5;272(2):382-93.
- (99) Azoury-Ziadeh R, Herd K, Fernando GJ, Lambert P, Frazer IH, Tindle RW. Low level expression of human papillomavirus type 16 (HPV16) E6 in squamous epithelium does not elicit E6 specific B- or T-helper immunological responses, or influence the outcome of immunisation with E6 protein. *Virus Res* 2001 Mar;73(2):189-99.
- (100) Evans DM, Frazer IH, Boomsma DI, Martin NG. Developmental genetics of red cell indices during puberty: a longitudinal twin study. *International Journal of Human Genetics* 2001;1(1):41-53.
- (101) Frazer IH, De Kluiver R, Leggatt GR, Guo HY, Dunn L, White O, et al. Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. *J Immunol* 2001 Dec 1;167(11):6180-7.
- (102) Liu WJ, Qi YM, Zhao KN, Liu YH, Liu XS, Frazer IH. Association of bovine papillomavirus type 1 with microtubules. *Virology* 2001 Apr 10;282(2):237-44.
- (103) Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJP, Frazer IH. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. *Vaccine* 2001 Dec 12;20(5-6):862-9.
- (104) Liu Y, Frazer IH, Liu WJ, Liu XS, McMillan NA, Zhao KN. Efficiency of delivery of DNA to cells by bovine papillomavirus type-1 L1/L2 pseudovirions. *Appl Microbiol Biotechnol* 2001;56:150-6.
- (105) Pettit AR, Weedon H, Ahern M, Zehntner S, Frazer IH, Slavotinek J, et al. Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis. *Rheumatology (Oxford)* 2001 Nov;40(11):1243-55.
- (106) Tindle RW, Herd K, Doan T, Bryson G, Leggatt GR, Lambert P, et al. Nonspecific down-regulation of CD8<sup>+</sup> T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter. *J Virol* 2001 Jul;75(13):5985-97.
- (107) Dale CJ, Liu XSS, De Rose R, Purcell DFJ, Anderson J, Xu Y, et al. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: Immunogenicity and protective efficacy in macaques. *Virology* 2002 Sep 15;301(1):176-87.
- (108) Fernando GJP, Khammanivong V, Leggatt GR, Liu WJ, Frazer IH. The number of long-lasting functional memory CD8<sup>+</sup> T cells generated depends on the nature of the initial non-specific stimulation. *Eur J Immunol* 2002;32(6):1541-9.
- (109) Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH, Fernando GJ. Antigen-specific CD4<sup>+</sup> T-cell help is required to activate a memory CD8<sup>+</sup> T cell to a fully functional tumor killer cell. *Cancer Res* 2002 Nov 15;62(22):6438-41.
- (110) Leggatt GR, Dunn LA, De Kluiver R, Stewart T, Frazer IH. Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. *Immunol Cell Biol* 2002;80(5):415-24.
- (111) Liu WJ, Gao FG, Zhao KN, Zhao WM, Fernando GJG, Thomas R, et al. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. *Virology* 2002 Sep 15;301(1):43-52.
- (112) Liu XS, Liu WJ, Zhao KN, Liu YH, Leggatt GR, Frazer IH. Route of administration of chimeric BPV1 VLPs determines the character of the induced immune responses. *Immunol Cell Biol* 2002 Feb 20;80(1):21-9.

- (113) Liu Y, Liu X, Frazer IH. Immunogenicity study of HPV 6b virus-like particles. *Zhonghua Yi Xue Za Zhi* 2002 May 10;82(9):587-9.
- (114) Thompson AG, Pettit AR, Padmanabha J, Mansfield H, Frazer IH, Strutton GM, et al. Nuclear RelB<sup>+</sup> cells are found in normal lymphoid organs and in peripheral tissue in the context of inflammation, but not under normal resting conditions. *Immunol Cell Biol* 2002 Apr;80(2):164-9.
- (115) Zhao KN, Frazer IH. *Saccharomyces cerevisiae* is permissive for replication of bovine papillomavirus type 1. *J Virol* 2002 Dec;76(23):12265-73.
- (116) Zhao KN, Frazer IH. Replication of Bovine Papillomavirus Type 1 (BPV-1) DNA in *Saccharomyces cerevisiae* following Infection with BPV-1 Virions. *J Virol* 2002 Apr;76(7):3359-64.
- (117) Frazer IH, Leggatt GR, Matsumoto K, De Kluiver R, Quinn M, Nicklin J, et al. Immunotherapy for HPV associated pre-cancer. *Cancer Immunity* 2003;3 Suppl 1:25.
- (118) Khammanivong V, Liu XS, Liu WJ, Rodda SJ, Leggatt GR, Tindle RW, et al. Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. *Immunol Cell Biol* 2003 Feb;81(1):1-7.
- (119) Liu XS, Xu Y, Hardy L, Khammanivong V, Zhao W, Fernando GJ, et al. IL-10 mediates suppression of the CD8 T cell IFN $\gamma$  response to a novel viral epitope in a primed host. *J Immunol* 2003;171:4765-72.
- (120) Malcolm KM, Gill J, Leggatt GR, Boyd R, Lambert PF, Frazer IH. Expression of the HPV16E7 oncoprotein by thymic epithelium is accompanied by disrupted T cell maturation and a failure of the thymus to involute with age<sup>1</sup>. *Clin Dev Immunol* 2003;10(2-4):91-103.
- (121) Stewart TJ, Smyth MJ, Fernando GJ, Frazer IH, Leggatt GR. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. *Cancer Res* 2003 Jun 15;63(12):3058-60.
- (122) Zhao KN, Tomlinson L, Liu WJ, Gu W, Frazer IH. Effects of additional sequences directly downstream from the AUG on the expression of GFP gene. *Biochim Biophys Acta* 2003 Nov 30;1630(2-3):84-95.
- (123) Zhao KN, Liu WJ, Frazer IH. Codon usage bias and A+T content variation in human papillomavirus genomes. *Virus Res* 2003 Dec;98(2):95-104.
- (124) Evans DM, Zhu G, Duffy DL, Frazer IH, Montgomery GW, Martin NG. A major quantitative trait locus for CD4-CD8 ratio is located on chromosome 11. *Genes Immun* 2004 Aug 12.
- (125) Evans DM, Zhu G, Duffy DL, Montgomery GW, Frazer IH, Martin NG. Multivariate QTL linkage analysis suggests a QTL for platelet count on chromosome 19q. *Eur J Hum Genet* 2004 Oct;12(10):835-42.
- (126) Evans DM, Zhu G, Duffy DL, Montgomery GW, Frazer IH, Martin NG. Major quantitative trait locus for eosinophil count is located on chromosome 2q. *J Allergy Clin Immunol* 2004 Oct;114(4):826-30.
- (127) Fowler NL, Frazer IH. Mutations in TAP genes are common in cervical carcinomas. *Gynecol Oncol* 2004 Mar;92(3):914-21.
- (128) Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX<sup>®</sup> trade mark adjuvant in women with cervical intraepithelial neoplasia. *Vaccine* 2004 Nov 25;23(2):172-81.

- (129) Gu W, Li M, Zhao WM, Fang NX, Bu S, Frazer IH, et al. tRNASer(CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes. *Nucleic Acids Res* 2004;32(15):4448-61.
- (130) Leggatt GR, Narayan S, Fernando GJ, Frazer IH. Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes. *J Leukoc Biol* 2004 Oct;76(4):787-95.
- (131) Matsumoto K, Leggatt GR, Zhong J, Liu X, De Kluyver RL, Peters T, et al. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. *J Natl Cancer Inst* 2004 Dec 3;96(21):1611-9.
- (132) Stewart TJ, Fernando GJ, Frazer IH, Leggatt GR. Tumour susceptibility to innate and adaptive immunotherapy changes during tumour maturation. *Immunol Cell Biol* 2004 Oct;82(5):455-61.
- (133) Stewart TJ, Drane D, Malliaros J, Elmer H, Malcolm KM, Cox JC, et al. ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. *Vaccine* 2004 Sep 9;22(27-28):3738-43.
- (134) Yan M, Peng J, Jabbar IA, Liu X, Filgueira L, Frazer IH, et al. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. *Virology* 2004 Jul 1;324(2):297-310.
- (135) Zhong J, Matsumoto K, De Kluyver R, Fernando GJ, Leggatt GR, Frazer IH. Human growth hormone (hGH) presented by K14hGH-transgenic skin grafts induces a strong immune response but no graft rejection. *Immunol Cell Biol* 2004;82:577-86.
- (136) Juffs H, Fowler N, Saal R, Grimmer KL, Beasley S, O'Sullivan B, et al. B-CLL cells have reduced capacity to upregulate expression of MHC class I in response to IFN-g. *Pathology*. In press 2005.
- (137) Pinto LA, Castle PE, Roden RB, Harro CD, Lowy DR, Schiller JT, et al. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. *Vaccine* 2005 May 20;23(27):3555-64.
- (138) Yan M, Peng J, Jabbar IA, Liu X, Filgueira L, Frazer IH, et al. Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta. *Immunol Cell Biol* 2005 Feb 1;83(1):83-91.
- (139) Zhao KN, Gu W, Fang NX, Saunders NA, Frazer IH. Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo. *Mol Cell Biol* 2005 Oct;25(19):8643-55.
- (140) Iliadou A, Evans DM, Zhu G, Duffy DL, Frazer IH, Montgomery GW, et al. A Genome-wide Scan of red cell indices replicates linkage on chromosome 6q23-24. *J Med Genet* 2006 Sep 1.
- (141) Liu XS, Dyer J, Leggatt GR, Fernando GJ, Zhong J, Thomas R, et al. Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. *J Immunol* 2006 Sep 1;177(5):2873-9.
- (142) Peng JC, Abu BS, Richardson MM, Jonsson JJ, Frazer IH, Nielsen LK, et al. IL10 and IL12B polymorphisms each influence IL-12p70 secretion by dendritic cells in response to LPS. *Immunol Cell Biol* 2006 Apr;84(2):227-32.
- (143) Tabrizi SN, Frazer IH, Garland SM. Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia. *Int J Gynecol Cancer* 2006 May;16(3):1032-5.

- (144) Iliadou A, Evans DM, Zhu G, Duffy DL, Frazer IH, Montgomery GW, et al. Genomewide scans of red cell indices suggest linkage on chromosome 6q23. *J Med Genet* 2007 Jan;44(1):24-30.
- (145) Hausdorf K, Newman B, Whiteman D, Aitken J, Frazer I. HPV vaccination: what do Queensland parents think? *Aust N Z J Public Health*. 2007 Jun;31(3):288-9.
- (146) Gu W, Ding J, Wang X, de Kluiver RL, Saunders NA, Frazer IH, Zhao KN. Generalized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiation. *Nucleic Acids Res*. 2007;35(14):4820-32. Epub 2007 Jul 9.
- (147) Fang NX, Gu W, Ding J, Saunders NA, Frazer IH, Zhao KN. Calcium enhances mouse keratinocyte differentiation in vitro to differentially regulate expression of papillomavirus authentic and codon modified L1 genes. *Virology*. 2007 Aug 15;365(1):187-97. Epub 2007 Apr 25.
- (148) Carroll L, Frazer IH, Turner M, Marwick TH, Thomas R. Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis. *Arthritis Res Ther*. 2007;9(2):R39.
- (149) Leggatt GR, Frazer IH. HPV vaccines: the beginning of the end for cervical cancer. *Curr Opin Immunol*. 2007 Apr;19(2):232-8. Epub 2007 Feb 12. Review.
- (150) Zhong J, Hadis U, De Kluiver R, Leggatt GR, Fernando GJ, Frazer IH. TLR7 stimulation augments T effector-mediated rejection of skin expressing neo-self antigen in keratinocytes. *Eur J Immunol*. 2008 Jan;38(1):73-81.

#### REVIEW ARTICLES AND BOOK CHAPTERS

- (1) Frazer IH, Mackay IR. Fundamental and applied aspects of rheumatoid arthritis. *Med J Aust* 1983;1(11):516-8.
- (2) Frazer IH, Mackay IR. Immune responses to liver-specific lipoprotein and liver membrane antigen: a tabular interpretative review. *J Clin Lab Immunol* 1984;14(4):165-7.
- (3) Frazer IH, Gust I, Mackay IR. The 1984 international symposium on viral hepatitis. *Med J Aust* 1984;140:712-4.
- (4) Mackay IR, Frazer IH, Jordan TW. Autoimmune responses to host liver proteins. In: Vyas GN, Dienstag JL, Hoofnagle JH, editors. *Viral hepatitis and liver disease*. New York: Grune and Stratton; 1984. p. 181-90.
- (5) Mackay IR, Frazer IH. Autoantibodies, autoimmunity and chronic hepatitis. In: Chisari FV, editor. *Advances in hepatitis research*. New York: Masson publishing inc.; 1984. p. 179-89.
- (6) Frazer IH, Donald KJ. First International Conference on the Acquired Immunodeficiency Syndrome. *Med J Aust* 1985;143(1):31-4.
- (7) Frazer IH, Mulhall BP. Second International Conference on the acquired immune deficiency syndrome. *Med J Aust* 1986;145:524-9.
- (8) Mackay IR, Frazer IH, McNeilage LJ, Whittingham S. Auto-epitopes and autoimmune diseases. *Ann NY Acad Sci* 1986;475:59-65.
- (9) Tait BD, Rowley M, Mackay IR, Serjantson SW, Probert D, An JB, et al. Rheumatoid Arthritis. In: Aizawa M, editor. *HLA in Asia-Oceania*. Sapporo: Hokkaido University Press; 1986. p. 401-3.



- (10) Frazer IH, O'Connor DT, Kennedy L. Anogenital HPV infections: treating the lesions in both partners. *Curr Ther* 1990;32:37-54.
- (11) Tindle RW, Park D, Frazer IH. Immunology of papillomavirus infection of the human anogenital epithelium. *J Gynaecol Surg* 1990;6:11-21.
- (12) Tindle RW, Frazer IH. Immunology of anogenital human papillomavirus (HPV) infection. *Aust NZ J Obstet Gynaecol* 1990;30(4):370-5.
- (13) O'Connor DT, Frazer IH, Kennedy L. Precursors of cervical cancer - the male factor. In: Carenza L, Atlante G, Pozzi V, editors. *Recent Advances in Cervical Pathology and Colposcopy*. 1 ed. Camforth, U.K.: The Parthenon Publishing Group; 1991. p. 235-9.
- (14) Frazer IH, Tindle RW. Cell mediated immunity to papillomaviruses. *Papillomavirus Report* 1992;3:53-8.
- (15) Tindle RW, Frazer IH. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. *Curr Top Microbiol Immunol* 1994;186:217-53.
- (16) Frazer IH. Antigen recognition and self-non-self discrimination. In: Pender MP, McCombe PA, editors. *Autoimmune neurological disease*. Cambridge: Cambridge University Press; 1995. p. 1-13.
- (17) Tindle R, Frazer IH. Human papillomavirus infection, genital warts and cervical cancer: prospects for prophylactic and therapeutic vaccines. *Exp Opin Invest drugs* 1995;4(9):783-97.
- (18) Zhou J, Frazer IH. Papovaviridae: capsid structure and capsid protein function. *Papillomavirus Report* 1995;6(3):59-64.
- (19) Boyle MJ, Goldstein DA, Frazer IH, Sculley TB. Managing HIV. Part 3: Mechanisms of disease. 3.6 How HIV promotes malignancies. *Med J Aust* 1996;164(4):230-2.
- (20) Frazer IH. The role of vaccines in the control of STDs: HPV vaccines. *Genitourin Med* 1996;72(6):398-403.
- (21) Frazer IH. Immunology of papillomavirus infection. *Curr Opin Immunol* 1996;8(4):484-91.
- (22) Zhou J, Frazer IH. Papovaviridae: capsid structure and capsid protein function. In: Lacey CJN, editor. *Current Research on Papillomaviruses*. 1 ed. Leeds: Leeds University Press; 1996. p. 93-101.
- (23) Frazer IH, Dunn LA. Human Papillomaviruses. In: Ahmed R, Chen I, editors. *Chronic virus infections*. 1997.
- (24) Frazer IH. Strategies for immunoprophylaxis and immunotherapy of papillomaviruses. *Clin Dermatol* 1997 Mar;15(2):285-97.
- (25) Frazer IH, McMillan NA. Papillomatosis and condylomata acuminata. In: Stuart-Harris R, Penny RW, editors. *Clinical applications of the interferons*. London: Chapman and Hall Medical; 1997. p. 79-91.
- (26) Frazer IH. The role of the immune system in anogenital HPV. *Australasian Journal of Dermatology* 1997;38 S2:14.
- (27) Mackenzie JM, Bolton W, Cunningham A.L, Frazer I.H, Gowans E.J., Grohmann G.S., Hampson A.W., Herceg A., Jenkins L.C., Longbottom H., Saksena N., Selvey C.A., Smith, *Recent Advances in Microbiology*. 1997. Chapter 5

- (28) Tindle RW, Frazer IH. Vaccines against papillomaviruses. In: Levine A, Woodrow G, Kaper X, Cobon X, editors. *New Generation Vaccines*. 2nd ed. New York: Marcel Decker; 1997. p. 769-83.
- (29) Frazer IH. The role of the immune system in human papillomavirus infection. *J Obstet Gynecol* 1998 Jan 1;18(S2):S72-S75.
- (30) Saunders NA, Frazer IH. Simplifying the molecular mechanisms of HPV. *Dermatol Clin* 1998;16(4):823-8.
- (31) Frazer IH, Tindle R. Cell mediated immunity to papillomaviruses. In: Lacey CJN, editor. *Current Research on Papillomaviruses*. Leeds: Leeds University Press; 1999. p. 151-64.
- (32) Frazer IH, et al. The current status of development of prophylactic vaccines against Human Papillomavirus infection. Department of Vaccines and Other Biologicals, WHO, Geneva; 1999.
- (33) Leggatt GR, Frazer IH. Immunobiology of HPV infection. In: Tindle RW, editor. *Vaccines for Human Papillomavirus Infection and Anogenital Disease*. Austin, Texas: R.G.Landes Company; 1999. p. 13-31.
- (34) The mode of Action of Imiquimod in the treatment of external genital Warts [CD] 3M Pharmaceuticals; 1999.
- (35) Bosch FX, Rohan T, Schneider A, Frazer IH, Pfister H, Castellsague X, et al. Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference. *J Clin Pathol* 2001 Mar;54(3):163-75.
- (36) Frazer IH. Wart and Hepatitis Vaccines. In: Healy DL, Kovacs GT, McLachlan R, Rodriguez-Armas D, editors. *Reproductive Medicine in the Twentyfirst Century*. New York: The Parthenon Publishing Group; 2001. p. 173-81.
- (37) Frazer IH. Vaccines for papillomavirus infection. *Virus Res* 2002 Nov;89(2):271-4.
- (38) Lowy DR, Frazer IH. Chapter 16: Prophylactic human papillomavirus vaccines. *J Natl Cancer Inst Monogr* 2003;(31):111-6.
- (39) Frazer IH. Is vaccine therapy the future in cancer prevention? *Expert Opin Pharmacother* 2004;5(12):2427-34.
- (40) Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. *Nat Rev Immunol* 2004 Jan;4(1):46-55.
- (41) Frazer IH. Human Papillomavirus. In: de Quadros CA, editor. *Vaccines Preventing Disease and Protecting Health*. Washington, D.C.: PAHO; 2004. p. 140-4.
- (42) Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco EL, Frazer IH, et al. Cervical Cancer Control. Priorities and new directions. *Int J Cancer* 2004;108:329-33.
- (43) Basser RL, Edwards S, Frazer IH. Development of vaccines against human Papillomavirus. vaccines: frontiers in design and development. Wyndmonham, UK: Horizon Bioscience; 2005. p. 210-30.
- (44) Frazer IH. God's gift to women: the human papillomavirus vaccine. *Immunity* 2006 Aug;25(2):179-84.
- (45) Frazer IH, Cox J. Finding a vaccine for human papillomavirus. *Lancet* 2006 Jun 24;367(9528):2058-9.

- (46) Frazer IH, Cox JT, Mayeaux EJ, Jr., Franco EL, Moscicki AB, Palefsky JM, et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. *Pediatr Infect Dis J* 2006 Feb;25(2 Suppl):S65-81, quiz.
- (47) Frazer IH, Appleton S. Vaccines to prevent and treat human papillomavirus associated anogenital disease. In: Jordan JA, Singer A, editors. *The Cervix*. 2nd ed. Oxford: Blackwell Publishing Ltd; 2006. p. 609-20.
- (48) Frazer IH. Delivering Papillomavirus Vaccines When and Where They're Most Needed. *Hum Vaccin* 2006 Sep 1;2(5).
- (49) Frazer IH. Harnessing the immune system to prevent cervical cancer. *Cancer Forum* 2006;30(2):115-7.
- (50) Frazer IH. Chapter 8 HPV vaccines. *Int J Gynaecol Obstet* 2006 Nov;94 Suppl 1:S81-S88.
- (51) Frazer IH, Kefford R. Progress in Cancer Control: The Alan Coates effect. *Cancer Forum* 2006;30(2):96-7.
- (52) Stanley M, Lowy DR, Frazer IH. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. *Vaccine* 2006 Aug 21;24 Suppl 3:S106-S113.
- (53) Leggatt GR, Frazer IH. HPV vaccines: the beginning of the end for cervical cancer. *Curr Opin Immunol* 2007 Feb 9.
- (54) Frazer IH. HPV immunisation: a significant advance in cancer control. *Gynecol Oncol*. 2007 Nov;107(2 Suppl):S1.
- (55) Frazer IH, Lowy DR, Schiller JT. Prevention of cancer through immunization: Prospects and challenges for the 21st century. *Eur J Immunol*. 2007 Nov;37 Suppl 1:S148-55. Review.
- (56) Hausdorf K, Newman B, Whiteman D, Aitken J, Frazer I. HPV vaccination: what do Queensland parents think? *Aust N Z J Public Health*. 2007 Jun;31(3):288-9.

**APPENDIX B:**

AA= amino acid, CU= codon usage, mc= mammalian consensus, wt= wild-type, onc= oncogenic, non-onc= non-oncogenic, Sec seq= secretory sequence, N/A= not applicable

**Summary of Secretory E7 Construct Series 1 and 2**

Construct	Amino acid & Codon	Codon usage of Secretory Sequence	Codon usage of E7	E7 Protein
Control Constructs				
IgkC1	N/A	wt	wt	non-onc
IgkC2	N/A	mc	mc	non-onc
IgkC3	N/A	wt	wt	onc
IgkC4	N/A	mc	mc	onc
Secretory E7 construct series 1				
IgkS1-1	Ala GCG	wt	wt with all Ala gcg	non-onc
IgkS1-2	Ala GCA	wt	wt with all Ala gca	non-onc
IgkS1-3	Ala GCT	wt	wt with all Ala gct	non-onc
IgkS1-4	Ala GCC	wt	wt with all Ala gcc	non-onc
IgkS1-5	Arg AGG	wt	wt with all Arg agg	non-onc
IgkS1-6	Arg AGA	wt	wt with all Arg aga	non-onc
IgkS1-7	Arg CGG	wt	wt with all Arg cgg	non-onc
IgkS1-8	Arg CGA	wt	wt with all Arg cga	non-onc
IgkS1-9	Arg CGT	wt	wt with all Arg	non-onc

Construct	Amino acid & Codon	Codon usage of Secretory Sequence	Codon usage of E7	E7 Protein
IgkS1-10	Arg CGC	wt	cgt wt with all Arg cgc	non-onc
IgkS1-11	Asn AAT	wt	wt with all Asn aat	non-onc
IgkS1-12	Asn AAC	wt	wt with all Asn aac	non-onc
IgkS1-13	Asp GAT	wt with all Asp gat	wt with all Asp gat	non-onc
IgkS1-14	Asp GAC	wt with all Asp gac	wt with all Asp gac	non-onc
IgkS1-15	Cys TGT	wt	wt with all Cys tgt	non-onc
IgkS1-16	Cys TGC	wt	wt with all Cys tgc	non-onc
IgkS1-17	Glu GAG	wt with all Glu gag	wt with all Glu gag	non-onc
IgkS1-18	Glu GAA	wt with all Glu gaa	wt with all Glu gaa	non-onc
IgkS1-19	Gln CAG	wt	wt with all Gln cag	non-onc
IgkS1-20	Gln CAA	wt	wt with all Gln caa	non-onc
IgkS1-21	Gly GGG	wt with all Gly ggg	wt with all Gly ggg	non-onc
IgkS1-22	Gly GGA	wt with all Gly gga	wt with all Gly gga	non-onc
IgkS1-23	Gly GGT	wt with all Gly ggt	wt with all Gly ggt	non-onc
IgkS1-24	Gly GGC	wt with all Gly ggc	wt with all Gly ggc	non-onc

Construct	Amino acid & Codon	Codon usage of Secretory Sequence	Codon usage of E7	E7 Protein
IgkS1-25	His CAT	wt	wt with all His cat	non-onc
IgkS1-26	His CAC	wt	wt with all His cac	non-onc
IgkS1-27	Ile ATA	wt	wt with all Ile ata	non-onc
IgkS1-28	Ile ATT	wt	wt with all Ile att	non-onc
IgkS1-29	Ile ATC	wt	wt with all Ile atc	non-onc
IgkS1-30	Lys AAG	wt	wt with all Lys aag	non-onc
IgkS1-31	Lys AAA	wt	wt with all Lys aaa	non-onc
IgkS1-32	Phe TTT	wt	wt with all Phe ttt	non-onc L15F, L22F
IgkS1-33	Phe TTC	wt	wt with all Phe ttc	non-onc L15F, L22F
IgkS1-34	Ser AGT	wt with all Ser agt	wt with all Ser agt	non-onc
IgkS1-35	Ser AGC	wt with all Ser agc	wt with all Ser agc	non-onc
IgkS1-36	Ser TCG	wt with all Ser tcg	wt with all Ser tcg	non-onc
IgkS1-37	Ser TCA	wt with all Ser tca	wt with all Ser tca	non-onc
IgkS1-38	Ser TCT	wt with all Ser tct	wt with all Ser tct	non-onc
IgkS1-39	Ser TCC	wt	wt with all Ser tcc	non-onc
IgkS1-40	Thr ACG	wt with all Thr	wt with all Thr	non-onc

Construct	Amino acid & Codon	Codon usage of Secretory Sequence	Codon usage of E7	E7 Protein
IgkS1-41	Thr ACA	acg wt with all Thr aca	acg wt with all Thr aca	non-onc
IgkS1-42	Thr ACT	wt with all Thr act	wt with all Thr act	non-onc
IgkS1-43	Thr ACC	wt with all Thr acc	wt with all Thr acc	non-onc
IgkS1-44	Tyr TAT	wt	wt with all Tyr tat	non-onc
IgkS1-45	Tyr TAC	wt	wt with all Tyr tac	non-onc
IgkS1-46	Val GTG	wt with all Val gtg	wt with all Val gtg	non-onc
IgkS1-47	Val GTA	wt with all Val gta	wt with all Val gta	non-onc
IgkS1-48	Val GTT	wt with all Val gtt	wt with all Val gtt	non-onc
IgkS1-49	Val GTC	wt with all Val gtc	wt with all Val gtc	non-onc
IgkS1-50	Leu CTG	altered with Leu ctg	altered with Leu ctg	onc
IgkS1-51	Leu CTA	altered with Leu cta	altered with Leu cta	onc
IgkS1-52	Leu CTT	altered with Leu ctt	altered with Leu ctt	onc
IgkS1-53	Leu CTC	altered with Leu ctc	altered with Leu ctc	onc
IgkS1-54	Leu TTG	altered with Leu ttg	altered with Leu ttg	onc
IgkS1-55	Leu TTA	altered with Leu tta	altered with Leu tta	onc

Construct	Amino acid & Codon	Codon usage of Secretory Sequence	Codon usage of E7	E7 Protein
IgkS1-56	Pro CCG	altered with Pro ccg	altered with Pro ccg	onc
IgkS1-57	Pro CCA	altered with Pro cca	altered with Pro cca	onc
IgkS1-58	Pro CCT	altered with Pro cct	altered with Pro cct	onc
IgkS1-59	Pro CCC	altered with Pro ccc	altered with Pro ccc	onc
Secretory E7 construct series 2				
IgkS2-1	Ala GCG	mc	mc	linkerA-onc
IgkS2-2	Ala GCA	mc	mc	linkerA-onc
IgkS2-3	Ala GCT	mc	mc	linkerA-onc
IgkS2-4	Ala GCC	mc	mc	linkerA-onc
IgkS2-5	Arg AGG	mc	mc	linkerR-onc
IgkS2-6	Arg AGA	mc	mc	linkerR-onc
IgkS2-7	Arg CGG	mc	mc	linkerR-onc
IgkS2-8	Arg CGA	mc	mc	linkerR-onc
IgkS2-9	Arg CGT	mc	mc	linkerR-onc
IgkS2-10	Arg CGC	mc	mc	linkerR-onc
IgkS2-11	Asn AAT	mc	mc	linkerN-onc
IgkS2-12	Asn AAC	mc	mc	linkerN-onc
IgkS2-13	Asp GAT	wt with all Asp gat	wt with all Asp gat	onc
IgkS2-14	Asp GAC	wt with all Asp gac	wt with all Asp gac	onc
IgkS2-15	Cys TGT	wt	wt with all Cys tgt	onc
IgkS2-16	Cys TGC	wt	wt with all Cys	onc



Construct	Amino acid & Codon	Codon usage of Secretory Sequence	Codon usage of E7	E7 Protein
			tgc	
IgkS2-17	Glu GAG	wt with all Glu gag	wt with all Glu gag	onc
IgkS2-18	Glu GAA	wt with all Glu gaa	wt with all Glu gaa	onc
IgkS2-19	Gln CAG	wt	wt with all Gln cag	onc
IgkS2-20	Gln CAA	wt	wt with all Gln caa	onc
IgkS2-21	Gly GGG	wt with all Gly ggg	wt with all Gly ggg	onc
IgkS2-22	Gly GGA	wt with all Gly gga	wt with all Gly gga	onc
IgkS2-23	Gly GGT	wt with all Gly ggt	wt with all Gly ggt	onc
IgkS2-24	Gly GGC	wt with all Gly ggc	wt with all Gly ggc	onc
IgkS2-25	His CAT	mc	mc	linkerH-onc
IgkS2-26	His CAC	mc	mc	linkerH-onc
IgkS2-27	Ile ATA	wt	wt with all Ile ata	onc
IgkS2-28	Ile ATT	wt	wt with all Ile att	onc
IgkS2-29	Ile ATC	wt	wt with all Ile atc	onc
IgkS2-30	Lys AAG	mc	mc	linkerK-onc
IgkS2-31	Lys AAA	mc	mc	linkerK-onc
IgkS2-32	Phe TTT	mc	mc	linkerF-onc
IgkS2-33	Phe TTC	mc	mc	linkerF-onc

Construct	Amino acid & Codon	Codon usage of Secretary Sequence	Codon usage of E7	E7 Protein
IgkS2-34	Ser AGT	wt with all Ser agt	wt with all Ser agt	onc
IgkS2-35	Ser AGC	wt with all Ser agc	wt with all Ser agc	onc
IgkS2-36	Ser TCG	wt with all Ser tcg	wt with all Ser tcg	onc
IgkS2-37	Ser TCA	wt with all Ser tca	wt with all Ser tca	onc
IgkS2-38	Ser TCT	wt with all Ser tct	wt with all Ser tct	onc
IgkS2-39	Ser TCC	wt	wt with all Ser tcc	onc
IgkS2-40	Thr ACG	wt with all Thr acg	wt with all Thr acg	onc
IgkS2-41	Thr ACA	wt with all Thr aca	wt with all Thr aca	onc
IgkS2-42	Thr ACT	wt with all Thr act	wt with all Thr act	onc
IgkS2-43	Thr ACC	wt with all Thr acc	wt with all Thr acc	onc
IgkS2-44	Tyr TAT	mc	mc	linkerY-onc
IgkS2-45	Tyr TAC	mc	mc	linkerY-onc
IgkS2-46	Val GTG	wt with all Val gtg	wt with all Val gtg	onc
IgkS2-47	Val GTA	wt with all Val gta	wt with all Val gta	onc
IgkS2-48	Val GTT	wt with all Val gtt	wt with all Val gtt	onc
IgkS2-49	Val GTC	wt with all Val gtc	wt with all Val gtc	onc
IgkS2-	Asn AAT	wt	wt with all Asn	linkerN-non-onc


Construct	Amino acid & Codon	Codon usage of Secretory Sequence	Codon usage of E7	E7 Protein
11b IgkS2- 12b	Asn AAC	wt	aat wt with all Asn aac	linkerN-non-onc

### APPENDIX C

Amino Acid	Ranking of Immune Response Preferences for Synonymous Codons
Ala	$\text{Ala}^{\text{GCT}} > \text{Ala}^{\text{GCC}} > (\text{Ala}^{\text{GCA}}, \text{Ala}^{\text{GCG}})$
Arg	$(\text{Arg}^{\text{CGA}}, \text{Arg}^{\text{CGC}}, \text{Arg}^{\text{CGT}}, \text{Arg}^{\text{AGA}}) > (\text{Arg}^{\text{AGG}}, \text{Arg}^{\text{CGG}})$
Asn	$\text{Asn}^{\text{AAC}} > \text{Asn}^{\text{AAT}}$
Asp	$\text{Asp}^{\text{GAC}} > \text{Asp}^{\text{GAT}}$
Cys	$\text{Cys}^{\text{TGC}} > \text{Cys}^{\text{TGT}}$
Glu	$\text{Glu}^{\text{GAA}} > \text{Glu}^{\text{GAG}}$
Gln	$\text{Gln}^{\text{CAA}} = \text{Gln}^{\text{CAG}}$
Gly	$\text{Gly}^{\text{GGA}} > (\text{Gly}^{\text{GGG}}, \text{Gly}^{\text{GGT}}, \text{Gly}^{\text{GGC}})$
His	$\text{His}^{\text{CAC}} = \text{His}^{\text{CAT}}$
Ile	$\text{Ile}^{\text{ATC}} \gg \text{Ile}^{\text{ATT}} > \text{Ile}^{\text{ATA}}$
Leu	$(\text{Leu}^{\text{CTG}}, \text{Leu}^{\text{CTC}}) > (\text{Leu}^{\text{CTA}}, \text{Leu}^{\text{CTT}}) \gg \text{Leu}^{\text{TTG}} > \text{Leu}^{\text{TTA}}$
Lys	$\text{Lys}^{\text{AAG}} = \text{Lys}^{\text{AAA}}$
Phe	$\text{Phe}^{\text{TTT}} > \text{Phe}^{\text{TTC}}$
Pro	$\text{Pro}^{\text{CCC}} > \text{Pro}^{\text{CCT}} \gg (\text{Pro}^{\text{CCA}}, \text{Pro}^{\text{CCG}})$
Ser	$\text{Ser}^{\text{TCG}} \gg (\text{Ser}^{\text{TCT}}, \text{Ser}^{\text{TCA}}, \text{Ser}^{\text{TCC}}) \gg (\text{Ser}^{\text{AGC}}, \text{Ser}^{\text{AGT}})$
Thr	$\text{Thr}^{\text{ACG}} > \text{Thr}^{\text{ACC}} \gg \text{Thr}^{\text{ACA}} > \text{Thr}^{\text{ACT}}$
Tyr	$\text{Tyr}^{\text{TAC}} > \text{Tyr}^{\text{TAT}}$
Val	$(\text{Val}^{\text{GTG}}, \text{Val}^{\text{GTC}}) > \text{Val}^{\text{GTT}} > \text{Val}^{\text{GTA}}$

APPENDIX D

Antibody response



Cellular response

